ISiS will get approved by FDA with strict warning label restrictions & REMS by the FDA. There is a slim chance e FDA will require additional trials, but chances are higher that the FDA will approve it so that patients have a choice.
The market will choose Juxtapid as the safer treatment.
I will be surprised if ISIS gets approved. With a safer drug approved (AEGR), and with the increased cardiovascular and cancer risks of Kymo coupled with its high dropout rate, the FDA has nothing to gain and everything to lose by approving it. AEGR will probably dance around $22-$26 until then, and if ISIS is unapproved AEGR will jump to $30+